The role of prostate specific antigen measurement in the detection and management of prostate cancer - PubMed (original) (raw)
Review
The role of prostate specific antigen measurement in the detection and management of prostate cancer
A F Nash et al. Endocr Relat Cancer. 2000 Mar.
Abstract
The introduction of prostate specific antigen (PSA) testing has revolutionised the early detection, management and follow-up of patients with prostate cancer and it is considered to be one of the best biomedical markers currently available in the field of oncology. Its use with annual digital rectal examination in prostate cancer screening programmes has led to a marked change in the distribution of stage at presentation towards earlier disease and led to a significant increase in the detection of potentially curable disease. In order to improve the specificity of PSA testing and thereby reduce the number of unnecessary prostatic biopsies, a number of refinements of PSA evaluation have been proposed. These include free to total PSA ratio, PSA density, PSA density, PSA density of the transition zone, PSA velocity and age-specific PSA reference ranges. The utility of these approaches is considered in this review. The role of PSA monitoring in the detection of recurrence following radical prostatectomy and radiotherapy is discussed, as well as its role in monitoring patients treated with endocrine therapy is discussed, as well as its role in monitoring patients treated with endocrine therapy in terms of correlating PSA response with outcome, in detecting disease progression and in guiding the use of subsequent therapies. Large continuing multicentre screening and outcome studies will provide important information enabling greater refinement of the use of this important diagnostic and monitoring tool in the future detection and management of prostate cancer.
Similar articles
- Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M. Djavan B, et al. J Urol. 1998 Aug;160(2):411-8; discussion 418-9. J Urol. 1998. PMID: 9679889 - [Status of PSA determination for early detection of prostate carcinoma].
Hammerer P, Huland H. Hammerer P, et al. Versicherungsmedizin. 1995 Jun 1;47(3):83-6. Versicherungsmedizin. 1995. PMID: 7541925 Review. German. - Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Horninger W, et al. Eur J Cancer. 2000 Jun;36(10):1322-35. doi: 10.1016/s0959-8049(00)00113-1. Eur J Cancer. 2000. PMID: 10882875 Retracted. - Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Horninger W, et al. Eur Urol. 1999;35(5-6):523-38. doi: 10.1159/000019893. Eur Urol. 1999. PMID: 10325519
Cited by
- Bicalutamide: clinical pharmacokinetics and metabolism.
Cockshott ID. Cockshott ID. Clin Pharmacokinet. 2004;43(13):855-78. doi: 10.2165/00003088-200443130-00003. Clin Pharmacokinet. 2004. PMID: 15509184 Review. - Developmental exposure to estrogen alters differentiation and epigenetic programming in a human fetal prostate xenograft model.
Saffarini CM, McDonnell-Clark EV, Amin A, Huse SM, Boekelheide K. Saffarini CM, et al. PLoS One. 2015 Mar 23;10(3):e0122290. doi: 10.1371/journal.pone.0122290. eCollection 2015. PLoS One. 2015. PMID: 25799167 Free PMC article. - IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.
Azevedo A, Cunha V, Teixeira AL, Medeiros R. Azevedo A, et al. World J Clin Oncol. 2011 Dec 10;2(12):384-96. doi: 10.5306/wjco.v2.i12.384. World J Clin Oncol. 2011. PMID: 22171281 Free PMC article. - The AR dependent cell cycle: mechanisms and cancer relevance.
Schiewer MJ, Augello MA, Knudsen KE. Schiewer MJ, et al. Mol Cell Endocrinol. 2012 Apr 16;352(1-2):34-45. doi: 10.1016/j.mce.2011.06.033. Epub 2011 Jul 12. Mol Cell Endocrinol. 2012. PMID: 21782001 Free PMC article. Review. - Prostate-specific antigen kallikrein and the heart.
Patanè S. Patanè S. World J Cardiol. 2009 Dec 31;1(1):23-5. doi: 10.4330/wjc.v1.i1.23. World J Cardiol. 2009. PMID: 21160572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous